We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MMHD:TASEMenora Mivtachim Holdings Ltd. Analysis

Data as of 2026-03-14 - not real-time

ILA 50,070.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Menora Mivtachim is trading above its short‑term and medium‑term moving averages, reinforcing a bullish price direction while the relative strength index remains in a neutral zone, suggesting limited upside pressure. The MACD histogram has turned negative, hinting at emerging bearish momentum, and recent price action sits comfortably above the identified support level. Volatility is elevated, yet the stock’s beta is low, indicating that broader market swings have a muted impact on its price. The dividend yield is attractive relative to peers, but a negative free cash flow raises questions about long‑term payout sustainability. A discounted cash‑flow analysis points to a fair value considerably higher than the current market price, implying upside potential, whereas the price‑to‑book multiple is exceptionally high and the price‑earnings multiple exceeds the industry average, signaling possible overvaluation.
Overall, the company shows solid earnings and a respectable dividend, but the mix of technical bearish signals, high valuation multiples, and cash flow concerns suggest a cautious approach. Investors may find short‑term stability but should weigh the upside from valuation gaps against the risks of earnings sustainability and regulatory pressures.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price above short‑term averages
  • negative MACD histogram
  • elevated volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF valuation gap
  • stable earnings growth
  • attractive dividend yield

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • high price‑to‑book multiple
  • moderate growth outlook
  • cash‑flow sustainability concerns

Key Metrics & Analysis

Financial Health

Revenue Growth5.00%
Profit Margin10.75%
P/E Ratio18.6
ROE22.07%
ROA2.32%
Debt/Equity62.15
P/B Ratio366.0
Op. Cash FlowILA2.4B
Free Cash FlowILA-11718850560
Industry P/E16.4

Technical Analysis

TrendBullish
RSI56.2
SupportILA 43,340.00
ResistanceILA 53,990.00
MA 20ILA 49,270.00
MA 50ILA 44,461.60
MA 200ILA 32,557.65
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair ValueILA 88,284.81
GradeUndervalued
TypeBlend
Dividend Yield2.29%

Risk Assessment

Beta0.22
Volatility59.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.